Clinical utility of cytokeratins as tumor markers
Top Cited Papers
- 31 July 2004
- journal article
- review article
- Published by Elsevier BV in Clinical Biochemistry
- Vol. 37 (7), 529-540
- https://doi.org/10.1016/j.clinbiochem.2004.05.009
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Molecular architecture of intermediate filamentsBioEssays, 2003
- Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and PrognosisTumor Biology, 2003
- Evaluation of urine CYFRA 21‐1 for the detection of primary and recurrent bladder carcinomaCancer, 2002
- Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinomaCancer, 2001
- Effect of Mutation and Phosphorylation of Type I Keratins on Their Caspase-mediated DegradationPublished by Elsevier BV ,2001
- Immunohistochemical Profiles of 30 Monoclonal Antibodies against Cytokeratins 8, 18 and 19Tumor Biology, 2001
- COMPARATIVE SENSITIVITY OF URINARY CYFRA 21-1, URINARY BLADDER CANCER ANTIGEN, TISSUE POLYPEPTIDE ANTIGEN AND NMP22 TO DETECT BLADDER CANCERJournal of Urology, 1999
- Epitope Specificity of 30 Monoclonal Antibodies against Cytokeratin Antigens: The ISOBM TD5-1 WorkshopTumor Biology, 1998
- INTERMEDIATE FILAMENTS: Structure, Dynamics, Function and DiseaseAnnual Review of Biochemistry, 1994
- Clinical Significance of the Number of Positive Tumor Markers in Assisting the Diagnosis of Lung Cancer with Multiple Tumor Marker AssayOncology, 1990